David Savage, MD, PhD

David Savage, MD, PhD, discusses the greater significance of the PFS benefit observed in a trial of darovasertib plus crizotinib in patients with HLA-A*02:01–negative uveal melanoma.

Following the FDA approval of vusolimogene oderparepvec plus nivolumab, melanoma specialists are preparing for real-world clinical use while rethinking how to design future intratumoral therapy trials.

David Savage, MD, PhD, discusses the significance of abemaciclib's PFS benefit in liposarcoma and how he approaches getting patients access to it.